Scots choose chewy Lipitor but refuse Zytiga, Sycrest and Gilenya
This article was originally published in Scrip
Executive Summary
Scotland's health technology assessment body, the Scottish Medicines Consortium, has rejected several drugs, including the first MS pill, Novartis' Gilenya and Janssen-Cilag's Zytiga (abiraterone acetate) for prostate cancer, for use on the Scottish NHS because the submitting companies failed to argue an economic case for their drugs.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.